Sectors

ABUS
Arbutus Biopharma Corporation
5.08
1 x 5.09
1 x 5.08
bid
ask
+
0.01
0.20%
1 @ 07:53 PM
5.14 +0.06 (1.20%)
Ytd5.61%
1y36.93%
4.99
day range
5.11
3.50
52 week range
5.45
Open5.04Prev Close5.07Low4.99High5.11Mkt Cap1.01B
Vol3.56MAvg Vol2.73MEPS0.79P/E6.43Forward P/E-30.74
Beta0.60Short Ratio13.20Inst. Own72.25%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-1650-d Avg4.69200-d Avg4.481yr Est5.51

ABUS News

Bank of America Corp DE Has $7.58 Million Stock Position in Arbutus Biopharma Corporation $ABUS
defenseworld.net
Bank of America Corp DE Has $7.58 Million Stock Position in Arbutus Biopharma Corporation $ABUS

Bank of America Corp DE lowered its stake in Arbutus Biopharma Corporation (NASDAQ: ABUS) by 8.1% du

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
globenewswire.com
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Pri

WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Ar

Why Is Arbutus Biopharma Stock Gaining Friday?
benzinga.com
Why Is Arbutus Biopharma Stock Gaining Friday?

Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auc

benzinga.com
Arbutus Biopharma Plans To Commence Modified Dutch Auction Tender Offer To Repurchase Up To $230M Of

Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
globenewswire.com
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “D

WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Ar

Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)
defenseworld.net
Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ: ABUS - Get Free Report) and YD Bio (NASDAQ: YDES - Get Free Report) are b

benzinga.com
Arbutus Biopharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.014M Beat $700.000K Estimate

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.03) per share which missed the anal

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M

GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue
businesswire.com
GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced the launch of Invenia™ ABUS (Automated Breas

benzinga.com
Arbutus Biopharma Announces Filing Of Three International Lawsuits Seeking To Enforce Patents Protec

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
globenewswire.com
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech,

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce

Arbutus Biopharma: Moderna Validates My IP Bull Case
seekingalpha.com
Arbutus Biopharma: Moderna Validates My IP Bull Case

Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patent

benzinga.com
Arbutus Biopharma Q1 EPS $0.87 Beats $(0.04) Estimate, Sales $179.126M Beat $750.000K Estimate

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.87 per share which beat the analys

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation s

Europe Clears First Flu/COVID Combo Shot From Moderna
benzinga.com
Europe Clears First Flu/COVID Combo Shot From Moderna

Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data s

QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
benzinga.com
QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursda

U.S. stock futures up, QuidelOrtho shares down in pre-market trading. Allbirds, MIND, Arbutus Biopha

Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
benzinga.com
Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

J B Hunt Transport Services Inc (JBHT) stock rose in pre-market trading after beating earnings estim

benzinga.com
Arbutus Biopharma's Imdusiran Receives FDA's Fast Track Designation To Treat Chronic Hepatitis B

Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinica

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
globenewswire.com
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatiti

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdu

benzinga.com
Arbutus Biopharma Q4 EPS $(0.01) Beats $(0.03) Estimate, Sales $1.051M Miss $1.233M Estimate

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.01) per share which beat the analys

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
globenewswire.com
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of Dece

Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars
benzinga.com
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars

Moderna shares jump after a $950 million settlement over COVID-19 vaccine patents, easing investor c

Staar Surgical Posts Downbeat Q4 Results, Joins Webtoon Entertainment, Gitlab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
benzinga.com
Staar Surgical Posts Downbeat Q4 Results, Joins Webtoon Entertainment, Gitlab And Other Big Stocks M

Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

Box Inc (BOX) shares jump 6.2% in pre-market trading after beating earnings expectations with $305

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant
wsj.com
Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

The company will appeal to a federal circuit court to argue that it has limited liability due to its

benzinga.com
Roivant Sciences' Subsidiary, Arbutus Biopharma Sign $2.25B Settlement With Moderna To Resolve All U

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust l

Moderna Resolves Global Patent Litigation with Arbutus/Genevant
accessnewswire.com
Moderna Resolves Global Patent Litigation with Arbutus/Genevant

Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
globenewswire.com
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent u

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
globenewswire.com
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Mo

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent u

Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts
seekingalpha.com
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts

Arbutus Biotech faces a pivotal March jury trial against Moderna over LNP patent infringement, creat

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know
zacks.com
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know

Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the com

benzinga.com
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maint

benzinga.com
Arbutus Biopharma Q3 EPS $(0.04) Misses $(0.03) Estimate, Sales $529.000K Miss $1.267M Estimate

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.04) per share which missed the anal

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Strong financial position with cash, cash equivalents and marketable securities of $93.7M     Modern

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
globenewswire.com
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a poten

Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
zacks.com
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?

Here is how Arbutus Biopharma (ABUS) and Boston Scientific (BSX) have performed compared to their se

benzinga.com
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maint

benzinga.com
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday

benzinga.com
Earnings Scheduled For February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings

benzinga.com
Earnings Scheduled For November 7, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

benzinga.com
Earnings Scheduled For August 3, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings

benzinga.com
Earnings Scheduled For May 4, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a

benzinga.com
Earnings Scheduled For March 2, 2023

Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at

benzinga.com
Earnings Scheduled For November 9, 2022

Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly ear

benzinga.com
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cance

Here's a roundup of top developments in the biotech space over the last 24 hours:

benzinga.com
Earnings Scheduled For August 4, 2022

  Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for

benzinga.com
Earnings Scheduled For May 5, 2022

  Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During Thursday, 849 stocks hit new 52-week lows.

benzinga.com
Earnings Scheduled For March 3, 2022

  Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly ea